---
title: "poems cervical cancer screening"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-poems-cervical-cancer-screening.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# poems cervical cancer screening

                                                           POEMs
                                  Patient-Oriented Evidence That Matters

A Low FODMAP Diet Is Better Than an Oral                           a smartphone application that provided guidance for a low
Spasmolytic for Irritable Bowel Syndrome                           FODMAP diet and provided more than 100 recipes; the
                                                                   patients in the otilonium bromide intervention were given
Clinical Question                                                  40 mg three times daily. Groups were similar at baseline,
Is using a smartphone application to increase adherence to a       with a mean age of 41 years, and 76% were female. Analysis
low fermentable oligosaccharides, disaccharides, monosac-          was by intention to treat. The primary outcome was a clini-
charides, and polyols (FODMAP) diet or an oral antispas-           cally significant improvement of 50 points on the 500-point
modic agent (otilonium bromide [not available in the United        IBS-Symptom Severity Scale. A response was noted by more
States]) more effective for the treatment of irritable bowel       patients in the FODMAP group than in the otilonium bro-
syndrome (IBS)?                                                    mide group at four weeks (62% vs. 51%; P = .02; number
                                                                   needed to treat [NNT] = 9) and eight weeks (71% vs. 61%;
Bottom Line                                                        P = .03; NNT = 10). The average decline in the severity score
The pragmatic trial found a clinically meaningful benefit          was significantly higher in the FODMAP group (–97 vs. –77
of a low FODMAP diet, implemented using a smartphone               points; P = .02). There were no differences between groups
application, compared with an active medication. Because           in overall quality-of-life scales. The authors prespecified a
of its safety and low cost, the authors state that a low FOD-      subgroup analysis of the 309 patients (70%) who met the
MAP diet should be first-line therapy for patients with IBS.       Rome IV criteria for IBS. The benefit was greater in these
The process includes eliminating FODMAP foods from the             patients in terms of the percentage of responders (77% vs.
diet and reintroducing them one at a time until the offend-        62%; P = .004; NNT = 7). Adherence was higher for the diet
ing food or foods are identified. The smartphone application       than the medication (94% vs. 73%).
used in the Belgian study was in French and Dutch, but there       Study design: Randomized controlled trial (nonblinded)
are many highly rated applications available. (Level of Evi-       Funding source: Government
dence = 1b–)                                                       Allocation: Concealed
                                                                   Setting: Outpatient (any)
Synopsis
                                                                   Reference: Carbone F, Van den Houte K, Besard L, et al.; Dom-
Low FODMAP diets and otilonium bromide have been                   ino Study Collaborators. Diet or medication in primary care
shown in randomized trials to be effective for the treat-          patients with IBS: the DOMINO study–a randomised trial sup-
ment of IBS. FODMAPs are short-chain carbohydrates that            ported by the Belgian Health Care Knowledge Centre (KCE Trials
are poorly absorbed by some people. The trial enrolled pri-        Programme) and the Rome Foundation Research Institute. Gut.
                                                                   2022;71(11):2226-2232.
mary care patients who were diagnosed with IBS by their
physician. Patients with psychiatric comorbidity, who had          Mark H. Ebell, MD, MS
                                                                   Professor
used a FODMAP diet, or who had taken otilonium bro-                University of Georgia
mide were excluded. The dietary intervention consisted of          Athens, Ga.



  POEMs (patient-oriented evidence that matters) are pro-          Letrozole More Effective Than Clomiphene
  vided by Essential Evidence Plus, a point-of-care clinical
  decision support system published by Wiley-Blackwell. For        for Infertility Treatment Among Individuals With
  more information, see http://​​w ww.essentialevidenceplus.       Polycystic Ovary Syndrome
  com. Copyright Wiley-Blackwell. Used with permission.
  For definitions of levels of evidence used in POEMs, see         Clinical Question
  http://​​w ww.essentialevidenceplus.com/product/ebm_loe.         Is letrozole superior to clomiphene for infertility treat-
  cfm?show=oxford.
                                                                   ment among individuals with polycystic ovary syn-
  To subscribe to a free podcast of these and other POEMs          drome (PCOS)?
  that appear in AFP, search in iTunes for “POEM of the Week”
  or go to http://​​goo.gl/3niWXb.
                                                                   Bottom Line
  This series is coordinated by Natasha Pyzocha, DO,
  contributing editor.                                             The meta-analysis of randomized controlled trials showed
  A collection of POEMs published in AFP is available at
                                                                   that for individuals with PCOS, treatment of infertility with
  https://​​w ww.aafp.org/afp/poems.                               letrozole compared with clomiphene resulted in a higher
                                                                   rate of ovulation induction, more pregnancies, and more live

August 2023 ◆ Volume 108, Number 2                     www.aafp.org/afp                          American Family Physician 203
                                                               POEMS


births. The conclusions are less than certain due to the high      Synopsis
risk of bias in some studies. (Level of Evidence = 1a–)            The ISCHEMIA trial randomized 5,179 patients with mod-
                                                                   erate to severe reversible ischemic coronary artery disease to
Synopsis                                                           receive initial therapy with angiography plus revasculariza-
The authors conducted a meta-analysis of randomized con-           tion (75% percutaneous coronary intervention, 25% bypass
trolled trials (N = 29; 3,952 participants; 7,633 ovulation        surgery) and optimal medical therapy or optimal medical
induction cycles) to compare the effect of letrozole and clo-      therapy alone. Patients with left main stenosis, an ejection
miphene on fertility among individuals with PCOS. They             fraction of less than 35%, recent acute coronary syndrome,
included studies that met the criteria of diagnosis of PCOS        or angina that could not be treated medically were excluded.
based on the 2003 Rotterdam criteria, had timed intercourse           Groups were balanced at the start of the trial and analysis
or insemination, and reported at least one of the three            was by intention to treat. Approximately 80% of patients in
outcomes of interest. Seven studies were graded as having          the early intervention group were revascularized, whereas
a high risk of bias to one or more of the following: quasi-        only 23% of patients were ultimately revascularized because
randomization (n = 3), lack of fully described allocation          of ineffective medical therapy. The original report found
concealment (n = 3), lack of masking (n = 6), or differences       no difference in mortality between groups after 3.2 years.
between groups in duration of infertility (n = 1). Meta-           The current report extended the follow-up to a median of
analysis for all primary outcomes favored letrozole: ovula-        5.7 years. All-cause mortality was identical between groups
tion induction rate (22 studies; 6,862 participants; 67% vs.       (hazard ratio [HR] = 1.0; 95% CI, 0.85 to 1.18). Although
59%; relative risk [RR] = 1.14; 95% CI, 1.06 to 1.21; P < .001),   cardiovascular death was less likely for those in the initial
pregnancy rate (28 studies; 3,936 participants; 35% vs. 23%;       invasive group (HR = 0.78; 95% CI, 0.63 to 0.96), noncardio-
RR = 1.48; 95% CI, 1.34 to 1.63; P < .001), and live birth rate    vascular mortality was more likely (HR = 1.44; 95% CI, 1.08
(eight studies; 1,725 participants; 33% vs. 22%; RR = 1.49;        to 1.91). These mortality numbers were driven by patients
95% CI, 1.27 to 1.74; P < .001). The authors judged the cer-       with at least 70% obstruction of two or more vessels. For the
tainty of evidence to be low for ovulation induction rate and      48% of patients who did not have multivessel disease, there
moderate for pregnancy and live birth rate.                        was no difference in all-cause, cardiovascular, or noncardio-
Study design: Meta-analysis (randomized controlled trials)         vascular mortality between groups.
Funding source: Self-funded or unfunded                            Study design: Randomized controlled trial (single-blinded)
Setting: Various (meta-analysis)                                   Funding source: Industry and government
Reference: Liu Z, Geng Y, Huang Y, et al. Letrozole compared       Allocation: Concealed
with clomiphene citrate for polycystic ovarian syndrome:           Setting: Outpatient (specialty)
a systematic review and meta-analysis. Obstet Gynecol.
                                                                   Reference: Hochman JS, Anthopolos R, Reynolds HR, et al.;
2023;141(3):523-534.
                                                                   ISCHEMIA-EXTEND Research Group. Survival after invasive or
Linda Speer, MD                                                    conservative management of stable coronary disease. Circula-
Professor of Family Medicine                                       tion. 2023;147(1):8-19.
University of Toledo
Toledo, Ohio                                                       Mark H. Ebell, MD, MS
                                                                   Professor
                                                                   University of Georgia
Early Invasive Strategy Does Not Reduce Mortality                  Athens, Ga.

for Moderate to Severe Ischemic Heart Disease
After 5.8 Years                                                    Limited Benefit for Routine Cervical Cancer
                                                                   Screening With Cotesting vs. HPV Testing Alone
Clinical Question
For patients with moderate to severe reversible ischemic           Clinical Question
heart disease, does adding an initial invasive strategy to         Is the detection of high-grade cervical neoplasia superior
optimal medical therapy reduce mortality more than opti-           with primary human papillomavirus (HPV) testing alone or
mal medical therapy alone?                                         with cytology cotesting?

Bottom Line                                                        Bottom Line
An early invasive strategy for patients with moderate to           The results of this population-based retrospective Swedish
severe ischemic heart disease does not reduce mortality; at        cohort support HPV testing alone as a routine screening
best, it shifts mortality from cardiovascular to noncardio-        approach for cervical cancer. Among individuals confirmed
vascular causes for those with multivessel disease. (Level of      to have cervical intraepithelial neoplasia grade 2, grade 3, or
Evidence = 1b)                                                     cancer (CIN2+) by biopsy, cytology was positive in less than

204 American Family Physician                         www.aafp.org/afp                          Volume 108, Number 2 ◆ August 2023
0.02% of individuals with negative HPV results. The results
did not hold for testing based on clinical or unknown indi-
cations; 3.8% of individuals with CIN2+ would have been
                                                                                           Advertiser Index
missed without cytology in addition to HPV testing. (Level        AAFP . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  110*, 112*, 129*, 2nd Cover*
of Evidence = 2b)
                                                                  AFP Case Studies/AAFP  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  131
Synopsis
                                                                  Biktarvy/GILEAD SCIENCES .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 2nd Cover*
The study is a large, retrospective, population-based cohort
study (N = 208,701) that used Swedish registry data to assess     BioFire SpotFire/BIOMERIEUX .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 129*
cervical cancer screening outcomes with HPV testing alone
                                                                  Dexcom HCP/DEXCOM  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 135
vs. HPV testing with cytology. The authors included indi-
viduals 40 to 42 years of age in 2019 who had cervical cancer     FMX/AAFP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  133
testing (n = 18,674), 10,643 of which were the population of
interest (10,664 tests) and were part of the Swedish cervical     FP Comprehensive/AAFP  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  198
screening program. The remainder of testing was for clini-        NATIONAL CATTLEMEN’S BEEF ASSOCIATION . . . . . . . . . . . . . . . . .  121
cal (n = 4,529) or unknown (n = 3,481) indications. In most
cases, cotesting was on the same day (99.6%). Cotests out-        Shingrix HCP/GLAXOSMITHKLINE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 4th Cover
side of the 14-day window were excluded. There were 197
individuals who had a biopsy within six months of cotest-                                                                                                                                 *DOES NOT APPEAR IN ALL COPIES.
ing with positive results for CIN2+. Of these, 189 had both
positive cytology and HPV tests, six had negative cytology
with a positive HPV test, and two (less than 0.02%) had pos-                    Answers to This Issue’s CME Quiz
itive cytology with a negative HPV test. CIN2+ with posi-                       Q1. D                             Q4. A                              Q7. D                          Q10. D                            Q13. D
tive results from cytology and a negative HPV test was more                     Q2. D                             Q5. B                              Q8. D                          Q11. A                            Q14. A
common among individuals who were tested for clinical or                        Q3. A                             Q6. A                              Q9. D                          Q12. C                            Q15. A
unknown indications (11 out of 290 participants; 3.8%). The
prevalence of HPV vaccination in the population studied
was not provided.
Study design: Cohort (retrospective)
Funding source: Government
Setting: Population-based
Reference: Kleppe SN, Andersson H, Elfsröm KM, et al. Evalua-
tion of co-testing with cytology and human papillomavirus test-
ing in cervical screening. Prev Med. 2023;166:107364.

Linda Speer, MD
Professor of Family Medicine
University of Toledo
Toledo, Ohio


 Editor’s Note:​ Dr. Ebell is deputy editor for evidence-
 based medicine for AFP and cofounder and editor-in-chief of
 Essential Evidence Plus, published by Wiley-Blackwell. ■
